Clinical utility of 18F FDG-PET/CT in the detection of bone marrow disease in Hodgkin's lymphoma

British Journal of Radiology

Volumn 85, Issue 1016, 2012, Pages

  Muzahir, Saima ^a   Mian, M ^a   Munir, I ^a   Nawaz, M K ^a   Faruqui, Z S ^a   Mufti, K A ^a   Bashir, H ^a   Uddin, N ^a   Siddiqui, N ^a   Maaz, A U R ^a   Mahmood, M T ^a  

^a SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW DISEASE; CHILD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BONE MARROW CANCER; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; BONE MARROW NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY, COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84864854667     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/29583493     Document Type: Article

References (36)

1. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958-63. (Pubitemid 43733510)
2. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52:9-16. (Pubitemid 351351040)
3. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med Mol Imaging 1998;25:721-8. (Pubitemid 28377035)
4. Edeiken-Monroe B, Edeiken J, Kim EE. Radiological concepts of lymphoma of bone. Radiol Clin North Am 1990;28:841-64.
5. Guermazi A, Brice P, de Kerviler EE, Fermé C, Hennequin C, Meignin V, et al. Extranodal Hodgkin disease: spectrum of disease. Radiographics 2001;21:161-79. (Pubitemid 33707416)
6. Ponzoni M, Ciceri F, Crocchiolo R, Famoso G, Doglioni C. Isolated bone marrow occurrence of classic Hodgkin's lymphoma in an HIV-negative patient. Haematologica 2006;91:ECR04.
7. Gronich N, Radnay J, Shapiro H, Manor Y, Lahav M, Lishner M. Clinical outcome of low-grade NHL patients with bone marrow involvement. Eur J Clin Invest 2007;37:305-9. (Pubitemid 46439415)
8. Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito F, et al. A large-scale study of bone marrow involvement in patients with hodgkin's lymphoma. Clin Lymphoma 2004;5:50-5. (Pubitemid 39136443)
9. Gerard Moulin R, Elif H, Xaviar C, Pauline B, Didier D, Myriam B, et al. F18-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:1095-105.
10. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6, [Erratum in: J Clin Oncol 1990;8:1602]. (Pubitemid 19272832)
11. Franco V, Tripodo C, Rizzo A, Stella M, Florena AM. Bone marrow biopsy in Hodgkin's lymphoma. Eur J Haematol 2004;73:149-55. (Pubitemid 39062236)
12. Gossmann A, Eich HT, Engert A, Josting A, Müller RP, Diehl V, et al. CT and MR imaging in Hodgkin's disease - present and future. Eur J Haematol Suppl 2005;66:83-9. (Pubitemid 40873983)
13. Brennan DD, Gleeson T, Coate LE, Cronin C, Carney D, Eustace SJ. A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol 2005;185:711-16.
14. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272-8. (Pubitemid 34203488)
15. Gordon H, Sweet HH. A simple method for the silver impregnation of reticulin. American Journal of Pathology 1936;12:545.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
17. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)
18. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: What is the evidence base? Nucl Med Comm 2007;28:335-54. (Pubitemid 46569166)
19. Buchmann I, Reske SN. Novel imaging techniques in NHL: Clinical results with PET imaging. Ann Hematol 2001;80(Suppl. 3):B54-7.
20. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-34. (Pubitemid 47544887)
21. Howell SJ, Grey M, Chang J, Morgenstern GR, Cowan RA, Deakin DP, et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002;119:408-11. (Pubitemid 35365491)
22. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005;105:1875-80. (Pubitemid 40731767)
23. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009;94:550-65.
24. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FD-GPET/CT. Eur J Nucl Med Mol Imaging 2007;34:60-7. (Pubitemid 44885555)
25. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 1975;82:365-6.
26. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-9. (Pubitemid 28135606)
27. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-5. (Pubitemid 38297200)
28. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6. (Pubitemid 28193885)
29. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: a bicenter trial. Cancer 2001;91:889-99.
30. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002;16:337-45. (Pubitemid 34988272)
31. Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ. 18F-Fluorodeoxyglucose- positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J 2003;44:779-86. (Pubitemid 37408070)
32. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273-9.
33. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266-73. (Pubitemid 32291064)
34. Fuster D, Chiang S, Andreadis C, Guan L, Zhuang H, Schuster S, et al. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma? Nucl Med Comm 2006;27:11-15. (Pubitemid 44391834)
35. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med 2007;37:206-22. (Pubitemid 46517465)
36. Kwee TC, Kwee RM, Verdonck LF, Bierings MB, Nievelstein RA. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol 2008;141:60-8. (Pubitemid 351350610)